ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[Syringin improves myocardial mitochondrial dynamics and alleviates oxidative stress injury in septic mice by activating SIRT3].
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the protective effects of syringin against septic myocardial injury and explore the underlying mechanisms.
methodsThirty C57 mice were randomly assigned to receive sham operation with or without subsequent syringin treatment or sepsis modeling by cecal ligation and puncture (CLP) followed by intraperitoneal injection of saline, syringin, or both syringin and 3-TYP (an SIRT3 inhibitor). Cardiac function and myocardial injury of the mice were assessed with echocardiography and HE staining, and serum cTnT, LDH, MDA, SOD, and GSH-Px levels were detected using ELISA. ROS production and expressions of p-DRP1, MFN1, and NOX4 were detected with immunohistochemistry and immunofluorescence staining, and the expressions of the SIRT3/NOX2/p-DRP1 pathway proteins were determined with Western blotting. In primary culture of neonatal mouse cardiomyocytes (NMCMs) treated with lipopolysaccharide (LPS), the effects of syringin, syringin combined with 3-TYP, and honokiol on mitochondrial membrane potential and expression of the SIRT3/NOX2/p-DRP1 pathway were analyzed by immunofluorescence staining and Western blotting.
resultsCLP mice exhibited significant impairment of cardiac function, obvious myocardial injury, elevated serum cTnT and LDH levels, and increased expression of oxidative stress- and mitochondrial injury-related proteins. Syringin treatment significantly improved myocardial structure and cardiac function, attenuated oxidative stress, and reduced mitochondrial damage in the CLP mice. Treatment with 3-TYP significantly abolished the protective effects of syringin and resulted in increased MDA and cTnT levels, decreased SOD activity, elevated ROS production, and increased expressions of oxidative stress and mitochondrial injury markers. In NMCMs, LPS stimulation obviously reduced mitochondrial membrane potential, increased AC-SOD2, NOX2, and p-DRP1 expressions, and decreased MFN1 levels. Syringin significantly alleviated LPS-induced oxidative stress and mitochondrial dysfunction, and these effects were abolished by 3-TYP treatment or SIRT3 silencing.
conclusionsSyringin attenuates sepsis-induced myocardial injury by activating SIRT3 to improve cardiac function, suppress oxidative stress, and alleviate mitochondrial damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.